Published in Urol Oncol on June 18, 2008
DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol (2011) 1.92
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Bibliometric analysis on retinoblastoma literatures in PubMed during 1929 to 2010. Int J Ophthalmol (2011) 0.86
Constitutional and occupational risk factors associated with bladder cancer. Actas Urol Esp (2013) 0.84
Differences in the cancer burden among foreign-born and US-born Arab Americans living in metropolitan Detroit. Cancer Causes Control (2013) 0.75
Urinary tract cancers: An overview for general practice. J Family Med Prim Care (2017) 0.75
Exploration of the postponing mechanism that delays carcinoma onset. Cancer Cell Int (2010) 0.75
Rare but Lethal Disease of Childhood: Metastatic, Muscle Invasive Bladder Cancer. Pediatr Rep (2015) 0.75
Aggressive muscle-invasive bladder cancer with sarcomatoid differentiation in a 10-year-old girl: A case report. Exp Ther Med (2016) 0.75
Familial urothelial cell carcinoma of the bladder with autosomal dominant inheritance and late onset phenotype. Springerplus (2014) 0.75
Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families. Fam Cancer (2016) 0.75
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist (2007) 6.03
Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer (2003) 5.97
Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst (2003) 5.09
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer (2005) 4.80
Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet (2005) 4.47
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev (2007) 3.63
Second primary neoplasms in patients with retinoblastoma. Br J Cancer (1986) 3.57
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev (2000) 3.42
Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet (1986) 2.78
Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis (2005) 2.47
Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst (2004) 2.32
The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer (2000) 2.24
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet (2006) 2.22
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (1984) 2.17
A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol (1984) 1.99
An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J (2006) 1.80
Variability in caffeine metabolism. Clin Pharmacol Ther (1983) 1.74
Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer (1989) 1.69
Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol (1998) 1.69
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev (2007) 1.52
Costello syndrome: an overview. Am J Med Genet C Semin Med Genet (2003) 1.49
Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet (2005) 1.47
Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer (2004) 1.43
N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect (1979) 1.43
Familial aggregation of urothelial cell carcinoma. Int J Cancer (2002) 1.43
Retinoblastoma associated with other primary malignant tumours. Trans Ophthalmol Soc U K (1974) 1.33
Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945-1994. Int J Cancer (1996) 1.33
Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis (2004) 1.33
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics (2005) 1.32
Roles of FGF receptors in mammalian development and congenital diseases. Birth Defects Res C Embryo Today (2003) 1.30
Muir-Torre syndrome: Diagnostic and screening guidelines. Australas J Dermatol (2006) 1.26
Segregation analysis of urothelial cell carcinoma. Eur J Cancer (2006) 1.21
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer (1988) 1.19
A new familial cancer syndrome? A spectrum of malignant and benign tumors including retinoblastoma, carcinoma of the bladder and other genitourinary tumors, thyroid adenoma, and a probable case of multifocal osteosarcoma. J Natl Cancer Inst (1977) 1.18
Genetic instability in bladder cancer assessed by the comet assay. J Natl Cancer Inst (2003) 1.16
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med (2004) 1.14
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res (1987) 1.12
Familial and environmental interactions in bladder cancer risk. Int J Cancer (1985) 1.11
Sporadic bilateral retinoblastoma and 13q- chromosomal deletion. Med Pediatr Oncol (1976) 1.07
Life style and occupational risk factors for bladder cancer in Germany. A case-control study. Cancer (1992) 1.06
Familial bladder cancer in the National Swedish Family Cancer Database. J Urol (2001) 1.05
Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis (1992) 1.05
Environmental exposure and bladder cancer in young males. J Natl Cancer Inst (1973) 1.00
Bladder cancer in young women. Am J Epidemiol (1986) 0.93
The Lynch syndrome II and urological malignancies. J Urol (1990) 0.93
Scanning the horizon: what is the future of genome-wide association studies in accelerating discoveries in cancer etiology and prevention? Cancer Causes Control (2007) 0.91
Genetic and epigenetic aspects of bladder cancer. J Cell Biochem (2005) 0.90
Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. Int J Cancer (2007) 0.89
Early-onset low-grade papillary carcinoma of the bladder associated with Apert syndrome and a germline FGFR2 mutation (Pro253Arg). Am J Med Genet A (2006) 0.89
Familial transitional cell carcinoma of the bladder. J Urol (1975) 0.87
Excess of cancer deaths in close relatives of patients with bilateral retinoblastoma. Ophthalmologica (1984) 0.85
Bladder cancer risk as modified by family history and smoking. Cancer (2006) 0.84
Familial aggregation of bladder cancer stratified by smoking status. Epidemiology (1991) 0.84
Genetic association with bladder cancer. Br Med J (1979) 0.82
Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. Am J Clin Oncol (2004) 0.81
Familial aggregation of urothelial carcinoma. J Urol (1981) 0.81
CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour. Pharmacogenetics (2000) 0.81
Familial transitional cell carcinoma of renal pelvis and upper ureter. Urology (1986) 0.80
Familial occurrence of carcinoma of the ureter. J Urol (1966) 0.80
Genetically determined debrisoquine oxidation capacity in bladder cancer. Carcinogenesis (1984) 0.79
Germline translocation t(5;20)(p15;q11) and familial transitional cell carcinoma. J Urol (1996) 0.78
Mutagen sensitivity in patients with familial and non-familial urothelial cell carcinoma. Int J Cancer (2000) 0.78
A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients. Cancer (1991) 0.78
Absence of karyotype abnormalities in patients with familial urothelial cell carcinoma. Urology (2001) 0.77
Familial transitional cell carcinoma among the population of Iceland. J Urol (1997) 0.77
Familial carcinoma of ureters and other genitourinary organs. J Urol (1983) 0.77
Familial bladder cancer in an oncology clinic. Cancer Genet Cytogenet (1987) 0.76
Familial transitional cell carcinoma and the Lynch syndrome II. Br J Urol (1993) 0.76
Multifocal transitional cell carcinoma in a patient with hereditary nonpolyposis colon cancer. BJU Int (2003) 0.76
Urinary system tumours in a family. Eur J Cancer (1993) 0.76
CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. Int J Cancer (2005) 0.76
Genetic predisposition and cyclophosphamide treatment in a girl with bladder carcinoma? Med Pediatr Oncol (1995) 0.76
Genitourinary tumors in men with the Muir-Torre syndrome. J Am Acad Dermatol (1995) 0.76
Familial urinary bladder cancer. Semin Oncol (1979) 0.76
Familial factors in bladder carcinoma. J Urol (1979) 0.76
Familial profile of transitional cell carcinoma. Br J Urol (1976) 0.76
Abnormal tryptophan metabolism in a family with a history of bladder cancer. J Natl Cancer Inst (1976) 0.76
The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. Pharmacogenetics (1995) 0.76
No evidence for large-scale germline genomic aberrations in hereditary bladder cancer patients with high-resolution array-based comparative genomic hybridization. Cancer Epidemiol Biomarkers Prev (2006) 0.76
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. Am J Respir Crit Care Med (2010) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Cancer incidence in persons with Fanconi anemia. Blood (2002) 4.05
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63
Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol (2005) 3.50
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol (2010) 3.09
The landscape of recombination in African Americans. Nature (2011) 3.06
Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev (2002) 2.99
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Cigarette smoking and lung cancer: modeling effect modification of total exposure and intensity. Epidemiology (2007) 2.63
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Competing risks analysis of correlated failure time data. Biometrics (2007) 2.31
Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr (2008) 2.29
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst (2011) 2.13
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol (2005) 2.11
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat (2014) 2.10
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res (2013) 1.99
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Cigarette smoking and cancer risk: modeling total exposure and intensity. Am J Epidemiol (2007) 1.80
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer (2011) 1.74
Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Med Genet (2011) 1.73
The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol Oncol (2009) 1.70
Cancer in Fanconi anemia. Blood (2003) 1.63
Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. Am J Public Health (2009) 1.57
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. Am J Epidemiol (2004) 1.56
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev (2008) 1.51
Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis (2004) 1.47
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol (2010) 1.37
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet (2011) 1.36
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res (2009) 1.35
Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet (2013) 1.34
Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China. Int J Cancer (2005) 1.32
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood (2007) 1.32
Phenotype harmonization and cross-study collaboration in GWAS consortia: the GENEVA experience. Genet Epidemiol (2011) 1.29
B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom (2003) 1.26
Relative validity of a food frequency questionnaire with a meat-cooking and heterocyclic amine module. Cancer Epidemiol Biomarkers Prev (2004) 1.26
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer (2009) 1.22
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica (2009) 1.21
Intermediacy and gene-environment interaction: the example of CHRNA5-A3 region, smoking, nicotine dependence, and lung cancer. J Natl Cancer Inst (2008) 1.20
Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila) (2011) 1.19
Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet (2013) 1.19
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood (2006) 1.19
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. J Clin Oncol (2012) 1.15
LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Med Genet (2010) 1.11
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10
The association of a tobacco-specific biomarker and cigarette consumption and its dependence on host characteristics. Cancer Epidemiol Biomarkers Prev (2007) 1.10
Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. Br J Haematol (2007) 1.08
Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch Gen Psychiatry (2012) 1.08
Immunologic effects of dioxin: new results from Seveso and comparison with other studies. Environ Health Perspect (2002) 1.07
Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes Cancer (2008) 1.05
Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer (2005) 1.05
Sisters in hereditary breast and ovarian cancer families: communal coping, social integration, and psychological well-being. Psychooncology (2008) 1.05
Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med (2014) 1.04
Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. Anticancer Res (2005) 1.04
Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 1.04
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet (2012) 1.04
Green tea consumption, genetic susceptibility, PAH-rich smoky coal, and the risk of lung cancer. Mutat Res (2005) 1.03
Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics (2002) 1.02
A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol (2009) 1.02
Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res (2014) 1.02
Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomarkers Prev (2009) 1.01
Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer. BMC Complement Altern Med (2008) 1.01
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol (2007) 1.01
Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res (2007) 1.00
Overview of monoclonal B-cell lymphocytosis. Br J Haematol (2007) 1.00
Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat (2010) 1.00
Measuring alcohol consumption for genomic meta-analyses of alcohol intake: opportunities and challenges. Am J Clin Nutr (2012) 0.99